Safety and Immunogenicity Study of the New dHER2 Vaccine to Treat HER2-positive Metastatic Breast Cancer

NCT00140738 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

3

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms, Breast

Interventions

BIOLOGICAL: GSK Biologicals' 719125

Sponsor

GlaxoSmithKline